TV-44749 safety and effectiveness in adults with schizophrenia
About this title
Read the official source — NCT05693935Researchers compared TV-44749 and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.
Understand this study
What did researchers investigate?
Researchers compared TV-44749 and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Bentonville and 81 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 675
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, China, ...
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT05693935
- Official title
Show the full official title
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Bentonville, United States · Little Rock, United States · Rogers, United States
65 more locations
- Anaheim, United States
- Bellflower, United States
- Garden Grove, United States
- La Habra, United States
- Lemon Grove, United States
- Long Beach, United States
- Los Angeles, United States
- Orange, United States
- Pico Rivera, United States
- Riverside, United States
- San Diego, United States
- Santee, United States
- Sherman Oaks, United States
- Torrance, United States
- Hialeah, United States
- Hollywood, United States
- Homestead, United States
- Miami, United States
- Miami Lakes, United States
- Miami Springs, United States
- West Palm Beach, United States
- Atlanta, United States
- Decatur, United States
- Peachtree Corners, United States
- Chicago, United States
- Shreveport, United States
- Gaithersburg, United States
- Flowood, United States
- St Louis, United States
- Marlton, United States
- Charlotte, United States
- Dayton, United States
- North Canton, United States
- Oklahoma City, United States
- Austin, United States
- DeSoto, United States
- Irving, United States
- Richardson, United States
- Burgas, Bulgaria
- Kazanlak, Bulgaria
- Lovech, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Razgrad, Bulgaria
- Rousse, Bulgaria
- Sliven, Bulgaria
- Sofia, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- Beijing, China
- Hangzhou, China
- Hefei, China
- Jining Shi, China
- Nanchang, China
- Shanghai, China
- Tianjin, China
- Wuhan, China
- Xinxiang, China
- Zhumadian, China
- Bucharest, Romania
- Iași, Romania
- Adapazarı, Türkiye
- Ankara, Türkiye
- Bursa, Türkiye
- Türkiye
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared TV-44749 and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.
Who is behind this study?
The study sponsor is Teva Branded Pharmaceutical Products R&D LLC, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including TV-44749 and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
